Mylan-Biocon's breast cancer biosimilar gets ANVISA nod

Biosimilar trastuzumab, indicated for breast cancer treatment, has been co-developed by Biocon and Mylan.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news